# Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients

> **NCT00103610** · PHASE3 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 298 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin

## Interventions

- **DRUG:** Granulocyte colony-stimulating factor plus plerixafor
- **DRUG:** Granulocyte colony-stimulating factor plus placebo

## Key facts

- **NCT ID:** NCT00103610
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2006-07
- **Final completion:** 2007-12
- **Target enrollment:** 298 (ACTUAL)
- **Last updated:** 2014-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00103610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00103610, "Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00103610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*